GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (XBUL:PFE) » Definitions » Cyclically Adjusted Price-to-FCF

Pfizer (XBUL:PFE) Cyclically Adjusted Price-to-FCF : 7.33 (As of Jun. 05, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pfizer Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Pfizer's current share price is лв20.535. Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was лв2.80. Pfizer's Cyclically Adjusted Price-to-FCF for today is 7.33.

The historical rank and industry rank for Pfizer's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XBUL:PFE' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.09   Med: 14.49   Max: 21.47
Current: 7.58

During the past years, Pfizer's highest Cyclically Adjusted Price-to-FCF was 21.47. The lowest was 7.09. And the median was 14.49.

XBUL:PFE's Cyclically Adjusted Price-to-FCF is ranked better than
93.85% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.58 vs XBUL:PFE: 7.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pfizer's adjusted free cash flow per share data for the three months ended in Mar. 2025 was лв0.531. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is лв2.80 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pfizer's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted Price-to-FCF Chart

Pfizer Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.25 20.86 15.98 9.33 8.77

Pfizer Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.97 9.35 9.55 8.77 8.21

Competitive Comparison of Pfizer's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted Price-to-FCF falls into.


;
;

Pfizer Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pfizer's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=20.535/2.80
=7.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Pfizer's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.531/134.9266*134.9266
=0.531

Current CPI (Mar. 2025) = 134.9266.

Pfizer Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 1.050 100.684 1.407
201509 1.288 100.392 1.731
201512 1.161 99.792 1.570
201603 0.415 100.470 0.557
201606 0.866 101.688 1.149
201609 1.199 101.861 1.588
201612 1.478 101.863 1.958
201703 0.345 102.862 0.453
201706 0.780 103.349 1.018
201709 1.217 104.136 1.577
201712 1.785 104.011 2.316
201803 0.443 105.290 0.568
201806 0.985 106.317 1.250
201809 1.344 106.507 1.703
201812 1.160 105.998 1.477
201903 0.322 107.251 0.405
201906 0.611 108.070 0.763
201909 1.167 108.329 1.454
201912 1.092 108.420 1.359
202003 0.819 108.902 1.015
202006 0.944 108.767 1.171
202009 0.481 109.815 0.591
202012 1.456 109.897 1.788
202103 1.205 111.754 1.455
202106 3.246 114.631 3.821
202109 3.055 115.734 3.562
202112 1.459 117.630 1.674
202203 1.754 121.301 1.951
202206 2.224 125.017 2.400
202209 1.537 125.227 1.656
202212 2.260 125.222 2.435
202303 0.022 127.348 0.023
202306 -0.636 128.729 -0.667
202309 0.803 129.860 0.834
202312 1.262 129.419 1.316
202403 0.116 131.776 0.119
202406 -0.727 132.554 -0.740
202409 1.820 133.029 1.846
202412 1.743 133.157 1.766
202503 0.531 134.927 0.531

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (XBUL:PFE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pfizer Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.